RENAGEL

LOE Approaching

sevelamer hydrochloride

NDAORALTABLET
Approved
Jul 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7

Mechanism of Action

hydrochloride, a non-absorbed binding crosslinked polymer. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the…

Clinical Trials (5)

NCT00756860Phase 1Completed

A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)

Started May 2008
66 enrolled
Healthy Volunteers
NCT00441545Phase 3Completed

Head to Head Study Against Sevelamer Hydrochloride

Started Jan 2007
182 enrolled
Chronic Kidney Disease, Stage 5
NCT00268957Phase 3Completed

Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With CKD on Hemodialysis

Started Jan 2006
217 enrolled
Kidney DiseasesChronic Renal InsufficiencyEnd-Stage Renal Disease
NCT00440648Phase 2Completed

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

Started Mar 2005
80 enrolled
Chronic Kidney Disease
NCT01049815N/ACompleted

Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease

Started Feb 2005
175 enrolled
End Stage Renal DiseaseHemodialysisIntimal Media Thickness